Pfiz­er, My­lan deal takes a coro­n­avirus hit

Apart from R&D dis­rup­tion, an­oth­er ca­su­al­ty of the coro­n­avirus epi­dem­ic is deal­mak­ing, or in this case, com­plet­ing planned merg­ers. In Ju­ly 2019, Pfiz­er — My­lan’s man­u­fac­tur­ing part­ner for its flag­ship EpiPen — inked a deal to com­bine its off-patent drug busi­ness with the gener­ic drug­mak­er. The deal, which was ini­tial­ly ex­pect­ed to close mid-2020 will now close in the sec­ond half of the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER